BET inhibitor resistance emerges from leukaemia stem cells

Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic opportunity by directly targeting bromodomain proteins that bind acetylated chromatin marks(1,2). Early clinical trials have shown promise, especially in acute myeloid leukaem...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature
Hauptverfasser: Fong, Chun Yew, Gilan, Omer, Lam, Enid Y. N., Rubin, Alan F., Ftouni, Sarah, Tyler, Dean, Stanley, Kym, Sinha, Devbarna, Yeh, Paul, Morison, Jessica, Giotopoulos, George, Lugo, Dave, Jeffrey, Philip, Lee, Stanley Chun-Wei, Carpenter, Christopher, Gregory, Richard, Ramsay, Robert G., Lane, Steven W., Abdel-Wahab, Omar, Kouzarides, Tony, Johnstone, Ricky W., Dawson, Sarah-Jane, Huntly, Brian J. P., Prinjha, Rab K., Papenfuss, Anthony T., Dawson, Mark A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6069604/
https://ncbi.nlm.nih.gov/pubmed/26367796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature14888
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge